NEWPORT, Ky.--(BUSINESS WIRE)--Xanodyne Pharmaceuticals, Inc. today announced the appointment of Gary A. Shangold, M.D., FACOG to the position of chief medical officer with primary responsibility for leading the Company’s clinical drug development programs. Dr. Shangold will report directly to Greg Flexter, president and chief executive officer. In addition, Timothy Arendt was appointed vice president of sales responsible for managing the sales operations and will also report to Flexter. These appointments fill key executive ranks as the Company focuses on advancing its late stage clinical development pipeline in women’s healthcare and pain management.
